StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$143.37−1.09 (-0.75%)

Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%

Merck operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Merck's operating cash flow for the twelve months ending Jun 30, 2026 was $19.97B, up 7.7% year over year. For fiscal 2025 it was $16.47B, down 23.3% from the year before. Over ten years it grew 2.8% a year on average. The highest annual figure on record is $21.47B in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.47B-23.3%
FY2024Dec 31, 2024$21.47B+65.1%
FY2023Dec 31, 2023$13.01B-31.9%
FY2022Dec 31, 2022$19.10B+45.5%
FY2021Dec 31, 2021$13.12B+72.3%
FY2020Dec 31, 2020$7.62B-14.3%
FY2019Dec 31, 2019$8.88B-18.7%
FY2018Dec 31, 2018$10.92B+69.3%
FY2017Dec 31, 2017$6.45B-37.8%
FY2016Dec 31, 2016$10.38B-17.2%
FY2015Dec 31, 2015$12.54B+56.9%
FY2014Dec 31, 2014$7.99B-31.4%
FY2013Dec 31, 2013$11.65B+16.3%
FY2012Dec 31, 2012$10.02B-19.1%
FY2011Dec 31, 2011$12.38B+14.4%
FY2010Dec 31, 2010$10.82B+219.0%
FY2009Dec 31, 2009$3.39B-48.4%
FY2008Dec 31, 2008$6.57B-6.1%
FY2007Dec 31, 2007$7.00B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.37B+63.1%
Q1 FY2026Mar 31, 2026$3.92B+56.7%
Q4 FY2025Dec 31, 2025$2.86B-17.2%
Q3 FY2025Sep 30, 2025$7.82B-15.8%
Q2 FY2025Jun 30, 2025$3.29B-41.6%
Q1 FY2025Mar 31, 2025$2.50B-19.1%
Q4 FY2024Dec 31, 2024$3.45B+1302.4%
Q3 FY2024Sep 30, 2024$9.29B+20.4%
Q2 FY2024Jun 30, 2024$5.64B+52.2%
Q1 FY2024Mar 31, 2024$3.09B+130.8%
Q4 FY2023Dec 31, 2023$246.00M-94.4%
Q3 FY2023Sep 30, 2023$7.72B+37.8%
Q2 FY2023Jun 30, 2023$3.70B-13.9%
Q1 FY2023Mar 31, 2023$1.34B-71.9%
Q4 FY2022Dec 31, 2022$4.43B-13.1%
Q3 FY2022Sep 30, 2022$5.60B+16.8%
Q2 FY2022Jun 30, 2022$4.30B+116.2%
Q1 FY2022Mar 31, 2022$4.76B+284.0%
Q4 FY2021Dec 31, 2021$5.10B+49.4%
Q3 FY2021Sep 30, 2021$4.80B+203.2%
Q2 FY2021Jun 30, 2021$1.99B+3.8%
Q1 FY2021Mar 31, 2021$1.24B+75.4%
Q4 FY2020Dec 31, 2020$3.41B+1332.8%
Q3 FY2020Sep 30, 2020$1.58B-62.6%
Q2 FY2020Jun 30, 2020$1.92B-37.8%
Q1 FY2020Mar 31, 2020$707.00M-47.1%
Q4 FY2019Dec 31, 2019$238.00M-93.4%
Q3 FY2019Sep 30, 2019$4.23B+51.3%
Q2 FY2019Jun 30, 2019$3.08B-8.8%
Q1 FY2019Mar 31, 2019$1.34B+15.7%
Q4 FY2018Dec 31, 2018$3.59B-10.6%
Q3 FY2018Sep 30, 2018$2.79B–
Q2 FY2018Jun 30, 2018$3.38B+2.0%
Q1 FY2018Mar 31, 2018$1.16B+303.8%
Q4 FY2017Dec 31, 2017$4.02B+10.7%
Q3 FY2017Sep 30, 2017-$1.17B-139.4%
Q2 FY2017Jun 30, 2017$3.32B–
Q1 FY2017Mar 31, 2017$286.00M–
Q4 FY2016Dec 31, 2016$3.63B–
Q3 FY2016Sep 30, 2016$2.97B–

More Merck figures

See a number that looks wrong?